Targeting GTP-binding protein GEM (Kir/Rad-associated GTPase) for oncological metastasis, cytoskeletal dynamics, and calcium channel regulation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GEM drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GEM Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for binding and biochemical assays. |
View GEM Products |
| Gene Delivery | GEM Promise-ORF / Lentivirus Full-length ORF for stable cell line construction to evaluate calcium channel trafficking and cell motility. |
View GEM Products |
| Benchmark Ab | Anti-GEM Recombinant Antibody High-affinity positive control clone for immunoprecipitation, western blot, and functional blocking validation. |
View GEM Products |
| Validator | GEM siRNA Set Target-specific knockdown pool for functional validation and target specificity verification in phenotypic assays. |
View GEM Products |
| Related Target A | CACNA1C (CaV1.2) Primary functional partner; GEM directly binds CaV beta subunits to inhibit CACNA1C cell-surface trafficking. |
View CACNA1C Products |
| Related Target B | RRAD (Rad GTPase) RGK family homolog; essential counter-screening target to ensure drug candidate selectivity. |
View RRAD Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GTPase Conformational Instability | Sequence Verified, Native-like folding, and strictly controlled storage conditions to preserve active GTP/GDP binding states. |
| RGK Subfamily Cross-Reactivity | Homolog panel proteins (Rad, Rem) available with high purity (>95%) for rigorous selectivity counter-screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and reference clones included |
| False Positives | Validated siRNA sets included for target-specific knockdown verification |
Live GEM R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the GEM GTPase (a member of the RGK family) represents an emerging frontier in oncology and channelopathy drug discovery. GEM acts as a critical molecular switch regulating both L-type calcium channel trafficking and actin cytoskeletal remodeling. In oncology, aberrant GEM overexpression drives epithelial-mesenchymal transition (EMT), cancer cell invasion, and chemoresistance in solid tumors. Concurrently, its role in suppressing voltage-gated calcium channels positions GEM as a novel target for neuropathic pain and cardiovascular indications.
The race for GEM therapeutics is intensifying, with major players shifting focus from traditional mAbs to small-molecule allosteric inhibitors and RNA-targeted therapeutics. As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific protein-protein interactions (PPI) between GEM and voltage-gated calcium channel beta-subunits (CaVβ), requiring highly specialized conformation-specific assay tools.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic Spin-offs, Biotech | Metastatic Breast Cancer, Neuropathic Pain | In vitro binding assays (Need high-purity GEM and CACNA1C/CaVβ recombinant proteins) |
| siRNA / Antisense | RNAi Therapeutics Specialists | Refractory Solid Tumors | In vitro knockdown validation (Need validated GEM siRNA and stable cell lines via Lentivirus) |
| Monoclonal Antibodies | Biopharma Corporates | Tumor Microenvironment Modulation | Epitope mapping and specificity screening (Need GEM native protein panels) |